<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03610945</url>
  </required_header>
  <id_info>
    <org_study_id>EDP 305-007</org_study_id>
    <nct_id>NCT03610945</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers</brief_title>
  <official_title>A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Fluconazole and Quinidine on the Pharmacokinetics and Safety of EDP-305 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized, 2-part, open-label, drug-drug interaction (DDI) study to evaluate
      the effect of concomitant administration of fluconazole or quinidine on the pharmacokinetics
      and safety of EDP-305 in healthy human volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2018</start_date>
  <completion_date type="Actual">August 21, 2018</completion_date>
  <primary_completion_date type="Actual">August 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>2-Part Single Group study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of EDP-305 with and without coadministration with fluconazole</measure>
    <time_frame>Up to 19 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of EDP-305 with and without coadministration with fluconazole</measure>
    <time_frame>Up to 19 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of EDP-305 with and without coadministration with quinidine</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of EDP-305 with and without coadministration with quinidine</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 25 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>EDP-305 and fluconazole interaction (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-305 and quinidine interaction (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>Subjects will receive fluconazole once daily from Day 5 to Day 18</description>
    <arm_group_label>EDP-305 and fluconazole interaction (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quinidine</intervention_name>
    <description>Subjects will receive quinidine twice daily from Day 5 to Day 12</description>
    <arm_group_label>EDP-305 and quinidine interaction (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-305</intervention_name>
    <description>Subjects will receive a single dose of EDP-305 on Day 1 and Day 14</description>
    <arm_group_label>EDP-305 and fluconazole interaction (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-305</intervention_name>
    <description>Subjects will receive a single dose of EDP-305 on Day 1 and Day 8</description>
    <arm_group_label>EDP-305 and quinidine interaction (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An informed consent document signed and dated by the subject.

          -  Healthy male and female subjects of any ethnic origin between the ages of 18 and 55
             years, inclusive.

          -  Female subjects must be of non-childbearing potential.

        Exclusion Criteria:

          -  Clinically relevant evidence or history of illness or disease.

          -  Pregnant or nursing females.

          -  History of febrile illness within 7 days prior to the first dose of study drug or
             subjects with evidence of active infection.

          -  A positive urine drug screen at screening or Day -1.

          -  Current tobacco smokers or use of tobacco within 3 months prior to screening.

          -  Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).

          -  History of regular alcohol consumption.

          -  Participation in a clinical trial within 30 days prior to the first dose of study
             drug.

          -  Clinically significant electrocardiogram abnormalities or QTcF greater than 450 ms for
             males and 470 ms for females at either Screening or Day -1 (Part 2 only), or any prior
             history of QT abnormality.

          -  For Part 2 subjects, the following cardiovascular abnormalities

               -  QRS duration &gt;110 ms

               -  Incomplete right bundle branch block or any complete bundle branch block

               -  Heart rate &lt;40 or &gt;90 beats per minute (per vital sign capture while rested)

               -  History of unexplained syncope, structural heart disease, or clinically
                  significant arrhythmias

               -  Personal or family history of long QT syndrome (genetically proven or suggested
                  by sudden death of a close relative due to cardiac causes at a young age) or
                  Brugada syndrome

               -  PR interval &gt;220 ms or any 2nd or 3rd degree AV block

               -  Ventricular pre-excitation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <role>Study Director</role>
    <affiliation>Enanta Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates, Inc.,</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>December 4, 2018</last_update_submitted>
  <last_update_submitted_qc>December 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug-drug interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Quinidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

